Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 4Plasma cell 2Myeloid 2Lymphoid 2Classical hematology 1

Conditions

Myelodysplastic Syndromes 41Leukemia, Myeloid, Acute 35Leukemia, Myelogenous, Chronic, BCR-ABL Positive 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Lymphoma, Non-Hodgkin 21Leukemia 19Hodgkin Disease 18Leukemia, Lymphocytic, Chronic, B-Cell 17Myeloproliferative Disorders 13Multiple Myeloma 13Lymphoma 13Primary Myelofibrosis 12Hematologic Neoplasms 11Leukemia, Myelomonocytic, Juvenile 9Graft vs Host Disease 8Leukemia, Myelomonocytic, Chronic 7Lymphoma, Mantle-Cell 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Follicular 6Lymphoma, B-Cell, Marginal Zone 6Lymphoma, Large-Cell, Immunoblastic 5Leukemia, Myeloid, Chronic-Phase 5Leukemia, Myeloid, Accelerated Phase 5Congenital Abnormalities 5Burkitt Lymphoma 5Waldenstrom Macroglobulinemia 4Leukemia, Neutrophilic, Chronic 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4Blast Crisis 4Recurrence 3

Interventions

Imatinib Mesylate 9fludarabine 5Whole-Body Irradiation 5Tacrolimus 5Mycophenolic Acid 5Cyclophosphamide 5Busulfan 5ponatinib 4nilotinib 4fludarabine phosphate 4Peripheral Blood Stem Cell Transplantation 4Cytarabine 3Bone Marrow Transplantation 3venetoclax 2thymoglobulin 2asciminib 2Sirolimus 2Patient Reported Outcome Measures 2Methotrexate 2Mesna 2Melphalan 2Dasatinib 2Behavior Therapy 2Azacitidine 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2zileuton 1spartalizumab 1sabatolimab 1nicotinamide-beta-riboside 1methanesulfonic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Myeloid × thymoglobulin × Myeloid × Clear all
NCT02916979 2023-10-18

FluBuATG

Dartmouth-Hitchcock Medical Center

Phase 1 Completed
20 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoid, Leukemia, Myeloid, Lymphoma, Waldenstrom Macroglobulinemia, Multiple Myeloma, Myelodysplastic Syndromes, Primary Myelofibrosis

NCT01392989 2019-05-07

Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders

Stanford University

Phase 2 Completed
44 enrolled 13 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neural Tube Defects

Data powered by HemOnc (CC BY 4.0) Colophon âš¡